$LXRX

Lexicon Pharmaceuticals (NASDAQ:LXRX) reported baseline data from its Phase 3 SONATA-HCM trial for sotagliflozin, enrolling 542 patients with hypertrophic cardiomyopathy. The study aims to measure symptom improvement using the KCCQ-CSS score, with topline results expected in Q1 2027. The trial includes patients with non-obstructive and obstructive HCM, with no FDA-approved treatments currently available for the former.

Lexicon Pharmaceuticals (LXRX) reported preclinical data showing sotagliflozin improved cardiac function in mice and reduced platelet activation. The company expects Phase 3 SONATA-HCM topline results in Q1 2027. The data aims to support ongoing clinical development and differentiation from SGLT2-only drugs.

Lexicon Pharmaceuticals (LXRX) stock rose nearly 6% after Cantor Fitzgerald analyst Steve Seedhouse initiated coverage with an overweight rating and $8 price target, citing potential FDA approval for sotagliflozin in treating hypertrophic cardiomyopathy. The drug is currently in late-stage development for this indication, with Seedhouse noting its unique mechanism could complement existing treatments.

Lexicon Pharmaceuticals (LXRX) shares rose 13% after Cantor Fitzgerald initiated coverage with an Overweight rating and $8.00 price target, citing potential in its HCM research. The firm believes sotagliflozin could succeed in Phase 3 trials and avoid competition, offering significant upside.

Lexicon Pharmaceuticals (LXRX) reported new Phase 3 data for sotagliflozin, showing consistent efficacy and safety across baseline systolic blood pressure in heart failure patients. The results were presented at ESC Congress 2026 and in JACC: Heart Failure. The company is unprofitable, with a net loss of $61.1 million in 2024, and relies on external funding. Analysts project $81.9 million in sales and $16.1 million in earnings by 2029, assuming 5.5% yearly revenue growth. The current share price

Lexicon Pharmaceuticals (LXRX) reported Q2 2026 revenue of $692,000, down from $28.87 million a year earlier, with a net loss of $31.78 million compared to prior net income of $3.25 million. The company's performance deterioration raises questions about its investment narrative, particularly its reliance on pipeline progress and partner milestones. The SONATA HCM Phase 3 trial for sotagliflozin remains a key long-term catalyst, with top-line data expected in early 2027.

Lexicon Pharmaceuticals (LXRX) completed Phase III enrollment in its SONATA HCM trial for sotagliflozin and set timelines for topline data and regulatory resubmissions. The article notes partner Viatris pursuing approvals outside the U.S. and Europe. LXRX shares were $2.34, with a $3.77 fair value claim and a 25.1x P/S ratio, alongside mention of quarterly losses and shelf registrations.

Lexicon (LXRX) discussed its Q2 2026 earnings call, focusing on sotagliflozin. The company said SONATA-HCM enrollment is complete and the trial was overenrolled, with top-line results expected in Q1 2027. For Zynquista, Lexicon said FDA resubmission criteria may be met after STENO1 reaches exposure targets by end of August, targeting an NDA resubmission in Q4 2026. It also noted Viatris regulatory progress for sotagliflozin and Novo Nordisk’s Phase I for 9851.

LEXICON PHARMACEUTICALS, INC. (LXRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 LEXICON PHARMACEUTICALS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS AND PROVIDES CLINICAL UPDATES Enrollment complete in Phase 3 SONATA-HCM study; top-line data expected Q1 2027 NDA resubmission activities for ZYNQUISTA ® in type 1 diabetes nearing completion Phase

Lexicon Pharmaceuticals (LXRX) completed patient randomization in its pivotal Phase 3 SONATA HCM trial of sotagliflozin for obstructive and non obstructive hypertrophic cardiomyopathy, with a key readout expected in early 2027. The stock closed at $2.34, up 50.97% over 90 days and 105.26% year to date. Simply Wall St cites a $3.77 fair value vs $2.34 close.